上述回复内容表明，中国科传近期股价异动并非由实控人层面的未披露重大信息或相关交易行为所引 发。公司后续如有需披露的重大事项，将严格按照相关法律法规的要求及时履行信息披露义务。 登录新浪财经APP 搜索【信披】查看更多考评等级 中国科技出版传媒股份有限公司（以下简称"中国科传"）的实际控制人中国科学院控股有限公司（以下 简称"中科院控股"）于2026年1月14日就上交所下发的《股票交易异常波动问询函》作出正式回复，明 确表示截至目前不存在涉及中国科传的应披露而未披露的重大信息，亦无处于筹划阶段的重大事项，且 在股票交易异常波动期间未买卖中国科传股票。 回复函中，中科院控股针对问询函关注的核心问题逐一作出说明。首先，在信息披露方面，中科院控股 确认不存在任何涉及中国科传的、根据法律法规及监管要求应予以披露而尚未披露的重大信息。其次， 关于重大事项筹划情况，中科院控股明确表示，截至目前，不存在处于筹划阶段的涉及中国科传的重大 事项，具体包括但不限于重大资产重组、股份发行、重大交易类事项、业务重组、股份回购、股权激 励、破产重整、重大业务合作、引进战略投资者等可能对公司股价产生重大影响的行为。 此外，中科院控股还就股 ...

证券日报网讯1月13日，海力风电（301155）在互动平台回答投资者提问时表示，根据《深圳证券交易 所创业板股票上市规则》的相关规定，上市公司预计年度经营业绩或者财务状况触及应当披露业绩预告 的情形的，应在会计年度结束之日起一个月内履行信息披露义务。公司将严格按照法律法规的要求及时 履行信息披露义务。 ...

Group 1 - The core viewpoint of the article is that Rongke Technology (300290) emphasizes its commitment to legal compliance in information disclosure to ensure fair access to information for all investors and to mitigate the impact of misinformation [1] Group 2 - The company responded to investor inquiries on its interactive platform, reinforcing its dedication to transparency and regulatory adherence [1] - The statement highlights the importance of reducing the influence of false information on investors [1]

Core Viewpoint - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Bureau due to violations related to the management and use of raised funds, specifically regarding the purchase of non-principal guaranteed financial products without adequate risk disclosure [1][2]. Group 1: Regulatory Actions - The Guangdong Securities Regulatory Bureau issued a warning letter to Guangkang Biochemical and its executives, Cai Danqun and Chen Haixia, for failing to fulfill their responsibilities under the Information Disclosure Management Measures [2]. - The company was found to have used raised funds to purchase 179 financial products, of which 158 were non-principal guaranteed, without sufficient disclosure of the associated risks in their reports [1][2]. Group 2: Financial Details - Guangkang Biochemical was listed on the Shenzhen Stock Exchange's ChiNext on June 27, 2023, issuing 18.5 million shares at a price of 42.45 yuan per share, which currently trades below its initial offering price [2]. - The total amount raised by the company was 785.325 million yuan, with a net amount of 697.3657 million yuan after deducting issuance costs, which exceeded the initially planned amount by 6.1779 million yuan [2].

Core Viewpoint - The Shanghai Stock Exchange has issued a regulatory letter to Jiabiyou, urging the company to respond promptly and fulfill its information disclosure obligations, potentially linked to a recent global recall of infant formula by Nestlé [1][2]. Group 1: Regulatory Actions - Jiabiyou received a regulatory letter from the Shanghai Stock Exchange on January 12, 2026, regarding the need to respond to the exchange's inquiries and fulfill disclosure obligations [2]. - The specific content of the regulatory letter from the Shanghai Stock Exchange remains unclear, but it is speculated to be related to Nestlé's recent recall of infant formula products [2]. Group 2: Market Impact and Company Response - Following the recall incident, Jiabiyou's stock price fell by 14.62% to 20.5 CNY per share on January 8, marking a nine-month low since April 10, 2025 [5]. - As of January 12, 2026, Jiabiyou's stock was trading at 20.45 CNY per share, with a total market capitalization of 3.442 billion CNY [5]. Group 3: Company Profile and Product Information - Jiabiyou is identified as the largest supplier of Arachidonic Acid (ARA) in China and a significant player in the international market [4]. - The company's main products include ARA, Docosahexaenoic Acid (DHA), β-Carotene (BC), N-Acetylneuraminic Acid (SA), and other related compounds [4].

Group 1 - The core viewpoint of the article emphasizes the importance of timely and accurate responses to investor inquiries as a key aspect of information disclosure and investor relations management for the company [1] - The company has established a comprehensive investor communication mechanism, requiring the board secretary office and relevant personnel to respond promptly to inquiries on the interactive platform [1] - Generally, the company aims to complete responses within two trading days; if further verification is needed, responses will be provided after the necessary checks [1] Group 2 - The company maintains a high level of response and timeliness rates on the interactive platform [1] - Future efforts will focus on optimizing processes to enhance response efficiency, thereby better meeting investor information needs [1]

（文章来源：证券日报） 证券日报网讯 1月9日，东方钽业在互动平台回答投资者提问时表示，深交所互动易作为投资者与公司 互动交流的平台，并非法定信息披露媒体。公司将严格遵守交易所信息披露相关法律法规，及时履行信 息披露义务；与公司经营情况相关内容请以公司在法定信息披露媒体发布的公告为准。 ...

Core Viewpoint - Chengdu Olin Biotechnology Co., Ltd. is facing a contract dispute involving two core vaccine products, leading to the freezing of some bank accounts, which has raised market concerns. The plaintiff claims a total of 19.2 million yuan in technical commissions and penalties, exceeding the company's net profit for the first half of 2025, highlighting potential risks in intellectual property compliance and information disclosure [1][4]. Group 1: Historical Cooperation and Disclosure Issues - The plaintiff asserts that a contract was signed in 2011, providing technical materials for specific vaccines, but no mention of this relationship was found in the company's IPO documentation from 2021, raising questions about the completeness of the IPO materials [5][6]. - The company emphasized its focus on independent research and collaboration with academic institutions in its prospectus, omitting the key technical provider, which could lead to regulatory scrutiny regarding compliance and potential omissions during the IPO process [5][6]. Group 2: Financial Impact of the Lawsuit - The frozen amount of 19.2 million yuan exceeds the company's net profit of 13.2 million yuan for the first half of 2025. Although the company claims the frozen accounts are not essential for operations, the liquidity pressure and financial risks cannot be overlooked [2][3]. - The two products involved in the lawsuit are projected to generate nearly 50 million yuan in revenue in 2024, with gross margins exceeding 76%, making them significant profit sources for the company. Any impact on production and sales due to the lawsuit could directly affect the company's performance [6][7]. Group 3: Legitimacy of Technology Sources - The company asserts that the products in question are legally marketed and compliant with regulations, claiming no rights defects. However, the plaintiff's claims challenge the legitimacy of the technology sources, which could jeopardize the company's rights and affect product qualifications and commercial sustainability if the court supports the plaintiff [7][8]. - The dispute reveals potential weaknesses in the company's early technology cooperation management, contract execution, and intellectual property compliance, which are critical for a technology-driven enterprise [7][8]. Group 4: Compliance and Transparency - The lawsuit, stemming from a contract signed 14 years ago, underscores the need for improved consistency in information disclosure and management of technology cooperation, as well as heightened awareness of legal risk prevention [3][8]. - In the context of stringent regulations and high compliance requirements in the pharmaceutical industry, companies must focus not only on product development and market expansion but also on strengthening internal controls and compliance measures to maintain transparency and stability in the eyes of investors and the market [3][8].

Core Viewpoint - Guangkang Biochemical (300804.SZ) received a warning letter from the Guangdong Securities Regulatory Bureau regarding the improper use of raised funds for cash management, specifically concerning the purchase of non-principal guaranteed financial products [1] Group 1: Regulatory Actions - The company was issued a warning letter (Decision No. [2025] 179) by the Guangdong Securities Regulatory Bureau [1] - The investigation covered the period from July 2023 to August 2025, during which the company used raised funds to purchase 179 financial products [1] Group 2: Financial Product Purchases - Out of the 179 financial products purchased, 158 were non-principal guaranteed products [1] - The breakdown of non-principal guaranteed product purchases was as follows: 14 in 2023, 68 in 2024, and 76 in 2025 [1] Group 3: Disclosure Issues - The company failed to adequately disclose the risks associated with purchasing non-principal guaranteed financial products in its annual reports [1] - Despite not incurring any principal losses, the company's actions did not comply with regulatory requirements outlined in the "Regulatory Guidelines for Listed Companies on the Management and Use of Raised Funds" [1]

Core Viewpoint - Guangkang Biotech (300804.SZ) received a warning letter from the Guangdong Securities Regulatory Bureau regarding the improper management of raised funds, specifically concerning the purchase of non-principal guaranteed financial products without adequate disclosure of associated risks [1] Group 1: Regulatory Actions - The company was issued a warning letter (Decision No. 〔2025〕179) by the Guangdong Securities Regulatory Bureau [1] - The investigation covered the period from July 2023 to August 2025, during which the company engaged in cash management using raised funds [1] Group 2: Fund Management Practices - The company executed 179 transactions to purchase financial products, of which 158 were non-principal guaranteed products [1] - The breakdown of non-principal guaranteed product purchases includes 14 in 2023, 68 in 2024, and 76 in 2025 [1] - The company failed to adequately disclose the risks of potential principal loss in its annual reports regarding the use of raised funds [1] Group 3: Compliance Violations - The company's actions were found to be non-compliant with the regulatory requirements outlined in the "Guidelines for the Supervision of Listed Companies on the Management and Use of Raised Funds" [1] - Violations included not fully disclosing the safety of principal when using raised funds for cash management [1]